+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Muscle Relaxant Drugs Market Size, Share & Trends Analysis Report By Drug Type (Skeletal Muscle Relaxant Drugs, Facial Muscle Relaxant Drugs), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2023
  • Region: Global
  • Grand View Research
  • ID: 5830971
Description Jump to:
The global muscle relaxant drugs market size is expected to reach USD 5.28 billion by 2030. The market is expected to expand at a CAGR of 4.38% from 2023 to 2030. The market is witnessing an increase in the use of relaxant drugs to treat muscle spasticity or spasms. This can be attributed to the growing geriatric population with musculoskeletal disorders, the rising number of surgical procedures, the sedentary lifestyle leading to back pain, work-related musculoskeletal disorders, and other factors leading to increased demand for such agents. For instance, according to an Elsevier article, a December 2021 research found that 64.0% of healthcare workers had a work-related musculoskeletal disease, with lower back pain being the most frequent complaint. Thus, the rising prevalence of such conditions offers a lucrative growth opportunity in the muscle relaxant drugs market.

The space has a presence of a diverse group of medications in the management of the condition. These include three FDA-approved drugs, baclofen, tizanidine, and dantrolene to treat spasticity, and six FDA-approved drugs, carisoprodol, metaxalone, methocarbamol, chlorzoxazone, orphenadrine, and cyclobenzaprine indicated to treat muscular spasms. Botulinum toxin is another approved drug for spasticity but is used only for certain cases.

Key market players are developing novel therapies and launching new products and generics in the market. For instance, in July 2021, Hikma Pharmaceuticals Plc. announced the launch of 20mg/ml Succinylcholine Chloride Injection indicated for skeletal muscle relaxation associated with surgery or mechanical ventilation in the U. S.; such neuromuscular blocking agents (example: succinylcholine, doxacurium, Cisatracurium, and rocuronium) are important during surgeries. In January 2022, Amneal Pharmaceuticals announced the acquisition of Saol's Baclofen franchise to augment the company's product portfolio with the segment's Lioresal, Lyvispah, and clinical products.

However, side effects associated with muscle relaxants might hamper the market's growth. For instance, in 2021, Sandoz recalled 13 lots of oral orphenadrine citrate 100 mg extended-release tablets. A nitrosamine above standard limits was identified in the lots during the testing, which can lead to cancer.

Muscle Relaxant Drugs Market Report Highlights

  • By drug type, the skeletal muscle relaxant drugssegment held the largest share of about 36.54% in 2022. This is attributed to the owing to the increasing prevalence of musculoskeletal problems and increasing customer awareness of their treatment and management
  • By route of administration, the oralsegment held a larger share of the global market. The use of oral muscle relaxants has upsurge due to high availability of products in the oral form and higher prescription rate
  • By distribution channel, the hospital pharmacysegment held a share of 46.76% in 2022, owing to the increasing amount of clinical and hospital consultations and treatment footfall
  • North America dominated the global market in 2022 due to the growth in the pharmaceutical industry, presence of high R&D investment, and the development of novel muscle relaxant drugs products in the region
  • Asia Pacific is expected to grow considerably in the future owing to the flourishing generic industry along with increasing investments by major market players to increase their presence in the region

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Growing geriatric population
3.4.2. Increasing prevalence of musculoskeletal disorders
3.5. Market Restraint Analysis
3.5.1. Adverse effects of muscle relaxants
3.6. Penetration and Growth Prospect Mapping 2022
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID - 19 Impact Analysis
Chapter 4. Drug Type Business Analysis
4.1. Muscle relaxant drugs market: Drug Type Movement Analysis
4.2. Skeletal Muscle Relaxant Drugs
4.2.1. Skeletal Muscle Relaxant Market, 2018 - 2030 (USD Million)
4.3. Facial Muscle Relaxant Drugs
4.3.1. Facial Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
4.4. Neuromuscular Blocking Agents
4.4.1. Neuromuscular Blocking Agents Market, 2018 - 2030 (USD Million)
Chapter 5. Route of Administration Business Analysis
5.1. Muscle relaxant drugs market: Route of Administration Movement Analysis
5.2. Oral Market, 2018 - 2030 (USD Million)
5.2.1. Oral Market, 2018 - 2030 (USD Million)
5.3. Injectable
5.3.1. Injectable Market, 2018 - 2030 (USD Million)
5.4. Others
5.4.1. Others Market ,2018 - 2030 (USD Million)
Chapter 6. Distribution Channel Business Analysis
6.1. Muscle relaxant drugs market: Distribution Channel Movement Analysis
6.2. Hospital Pharmacy
6.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
6.3. Retail Pharmacy
6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
6.4. Online Pharmacy
6.4.1. Online Pharmacy Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Muscle Relaxant Drugs Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Scenario
7.2.3.6. U.S. Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Reimbursement Scenario
7.2.4.6. Canada Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Scenario
7.3.3.6. Germany Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.4. UK
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Scenario
7.3.4.6. UK Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Scenario
7.3.5.6. France Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Scenario
7.3.6.6. Italy Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.7. Spain
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Scenario
7.3.7.6. Spain Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Scenario
7.3.8.6. Denmark Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.9. Sweden
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Scenario
7.3.9.6. Sweden Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.3.10. Norway
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Reimbursement Scenario
7.3.10.6. Norway Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Scenario
7.4.3.6. Japan Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.4. China
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Scenario
7.4.4.6. China Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.5. India
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Scenario
7.4.5.6. India Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Scenario
7.4.6.6. South Korea Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.7. Australia
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Scenario
7.4.7.6. Australia Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.4.8. Thailand
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. Reimbursement Scenario
7.4.8.6. Thailand Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.5.3. Brazil
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Scenario
7.5.3.6. Brazil Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Reimbursement Scenario
7.5.4.6. Mexico Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.5.5. Argentina
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Reimbursement Scenario
7.5.5.6. Argentina Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.6.3. South Africa
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Scenario
7.6.3.6. South Africa Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.6.4. Saudi Arabia
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Scenario
7.6.4.6. Saudi Arabia Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.6.5. UAE
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Scenario
7.6.5.6. UAE Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
7.6.6. Kuwait
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Competitive Scenario
7.6.6.4. Regulatory Framework
7.6.6.5. Reimbursement Scenario
7.6.6.6. Kuwait Muscle Relaxant Drugs Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. Amneal Pharmaceuticals LLC
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Ipsen Biopharmaceuticals, Inc.
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Merz Pharmaceuticals, LLC.
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Par Pharmaceutical
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Endo Pharmaceuticals
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Vertical Pharmaceuticals
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Mallinckrodt
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. SteriMax
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Eisai Co., Ltd.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Teva Pharmaceuticals USA, Inc.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 4. Global muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 5. Global muscle relaxant drugs market, by distribution channel, 2018 - 2030 (USD Million)
Table 6. Global muscle relaxant drugs market, by region, 2018 - 2030 (USD Million)
Table 7. North America muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 8. North America muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 9. North America muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 10. North America muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 11. U.S. muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 12. U.S. muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 13. U.S. muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 14. Canada muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 15. Canada muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 16. Canada muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 17. Europe muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 18. Europe muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 19. Europe muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 20. Europe muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 21. UK muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 22. UK muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 23. UK muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 24. Germany muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 25. Germany muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 26. Germany muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 27. France muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 28. France muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 29. France muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 30. Italy muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 31. Italy muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 32. Italy muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 33. Spain muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 34. Spain muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 35. Spain muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 36. Denmark muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 37. Denmark muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 38. Denmark muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 39. Sweden muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 40. Sweden muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 41. Sweden muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 42. Norway muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 43. Norway muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 44. Norway muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 45. Asia Pacific muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 46. Asia Pacific muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 47. Asia Pacific muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 48. Asia pacific muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 49. China muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 50. China muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 51. China muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 52. India muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 53. India muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 54. India muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 55. Japan muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 56. Japan muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 57. Japan muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 58. Thailand muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 59. Thailand muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 60. Thailand muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 61. Australia muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 62. Australia muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 63. Australia muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 64. South Korea muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 65. South Korea muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 66. South Korea muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 67. Latin America muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 68. Latin America muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 69. Latin America muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 70. Latin America muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 71. Brazil muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 72. Brazil muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 73. Brazil muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 74. Mexico muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 75. Mexico muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 76. Mexico muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 77. Argentina muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 78. Argentina muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 79. Argentina muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 80. Middle East & Africa muscle relaxant drugs market, by country, 2018 - 2030 (USD Million)
Table 81. Middle East & Africa muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 82. Middle East & Africa muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 83. Middle East & Africa muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 84. South Africa muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 85. South Africa muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 86. South Africa muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 87. Saudi Arabia muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 88. Saudi Arabia muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 89. Saudi Arabia muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 90. UAE muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 91. UAE muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 92. UAE muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
Table 93. Kuwait muscle relaxant drugs market, by drug type, 2018 - 2030 (USD Million)
Table 94. Kuwait muscle relaxant drugs market, by route of administration, 2018 - 2030 (USD Million)
Table 95. Kuwait muscle relaxant drugs market, distribution channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain - based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Muscle relaxant drugs, market segmentation
Fig. 8 Market snapshot, 2022
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (current & future impact)
Fig. 11 Market restraint relevance analysis (current & future impact)
Fig. 12 Market challenge relevance analysis (current & future impact)
Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Market penetration vs growth prospect mapping, 2022
Fig. 16 Global muscle relaxant drugs market: drug type movement analysis
Fig. 17 Global muscle relaxant drugs market, for skeletal muscle relaxant drugs, 2018 - 2030 (USD Million)
Fig. 18 Global muscle relaxant drugs market, for facial muscle relaxant drugs, 2018 - 2030 (USD Million)
Fig. 19 Global muscle relaxant drugs market, for neuromuscular blocking agents, 2018 - 2030 (USD Million)
Fig. 20 Global muscle relaxant drugs market: route of administration movement analysis
Fig. 21 Global muscle relaxant drugs market, for oral, 2018 - 2030 (USD Million)
Fig. 22 Global muscle relaxant drugs market, for injectable, 2018 - 2030 (USD Million)
Fig. 23 Global muscle relaxant drugs market: distribution channel movement analysis
Fig. 24 Global muscle relaxant drugs market, for hospital pharmacy, 2018 - 2030 (USD Million)
Fig. 25 Global muscle relaxant drugs market, for retail pharmacy, 2018 - 2030 (USD Million)
Fig. 26 Global muscle relaxant drugs market, for online pharmacy, 2018 - 2030 (USD Million)
Fig. 27 Regional marketplace: key takeaways
Fig. 28 Regional outlook, 2022 & 2030
Fig. 29 North America muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 30 U.S. muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 31 Canada muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 32 Europe muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 33 UK muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 34 Germany muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 35 France muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 36 Italy muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 37 Spain muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 38 Denmark muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 39 Sweden muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 40 Norway muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 41 Asia pacific muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 42 China muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 43 India muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 44 Japan muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 45 Thailand muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 46 Australia muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 47 South Korea muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 48 Latin America muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 49 Brazil muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 50 Mexico muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 51 Argentina muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 52 Middle East and Africa muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 53 South Africa muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 54 Saudi Arabia muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 55 UAE muscle relaxant drugs market, 2018 - 2030 (USD Million)
Fig. 56 Kuwait muscle relaxant drugs market, 2018 - 2030 (USD Million)

Companies Mentioned

  • Amneal Pharmaceuticals LLC
  • Ipsen Biopharmaceuticals, Inc.
  • Merz Pharmaceuticals, LLC.
  • Par Pharmaceutical
  • Endo Pharmaceuticals
  • Vertical Pharmaceuticals
  • Mallinckrodt
  • SteriMax
  • Eisai Co., Ltd.
  • Teva Pharmaceuticals USA, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 3.74 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.28 Billion
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Muscle Relaxants Drug Market by Drug, Distribution - Global Forecast 2025-2030 - Product Image

Muscle Relaxants Drug Market by Drug, Distribution - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Muscle Relaxant Drugs Global Market Report 2024 - Product Image

Muscle Relaxant Drugs Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Muscle Relaxant Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Muscle Relaxant Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 86 Pages
  • Global
From
2024 Global Forecast for Skeletal Muscle Relaxants (2025-2030 Outlook) - Manufacturing & Markets Report - Product Image

2024 Global Forecast for Skeletal Muscle Relaxants (2025-2030 Outlook) - Manufacturing & Markets Report

  • Report
  • 132 Pages
  • Global
From
Degenerative Disc Disease Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, and Injectable), By Drugs, By End Use (Hospitals, Clinics, and Others), By Treatment Type, By Regional Outlook and Forecast, 2024 - 2031 - Product Image

Degenerative Disc Disease Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, and Injectable), By Drugs, By End Use (Hospitals, Clinics, and Others), By Treatment Type, By Regional Outlook and Forecast, 2024 - 2031

  • Report
  • 300 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.